关键词：囊性纤维化；粘液粘稠病；遗传性疾病；慢性疾病
摘 要：Cystic fibrosis, also known as mucoviscidosis, is a rare genetic disease more prevalent among Caucasians. It is one of the most common types of genetic diseases observed in Caucasian children. Though no precise data is available in Europe, cystic fibrosis is estimated to affect 1 in 8,000-10,000 individuals. Cystic fibrosis is a chronic disease and usually progressive in nature. Onset of the disease occurs in early childhood or, rarely, at birth. Adolescent diabetes, chronic bronchitis, pancreatitis, male sterility, high salt content in sweat, difficulties in breathing and digestion, secretion of abnormal viscous mucus, growth anomalies, and, very rarely, intestinal obstruction or liver cirrhosis are the major symptoms of the disease. The degree of bronchopulmonary involvement determines the morbidity and mortality of the patient.
目 录：

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

03.1 Market Overview

03.2 Product Offerings

04. Market Research Methodology

04.1 Market Research Process

04.2 Research Methodology

05. Product Profiles

Zenpep

Colomycin/Colobreathe

Pulmozyme

Cayston

TOBI/TOBI Podhaler

Kalydeco

06. Introduction

07. Disease Overview

07.1 Understanding Cystic Fibrosis

07.2 Pathophysiology

07.3 Epidemiology

Global

UK

07.4 Diagnosis

Carrier Testing

Antenatal Testing

Newborn Screening

Other Tests

07.5 Manifestations of Cystic Fibrosis

07.6 Economic Burden

08. Pipeline Portfolio

09. Market Landscape

09.1 Market Overview

09.2 Market Size and Forecast

09.3 Five Forces Analysis

10. Market Segmentation by Molecule Type

10.1 Biologics

Enzymes

10.2 Small Molecules

CFTR Modulators

Antibiotics

11. Market Segmentation by Route of

Administration

11.1 Topical

11.2 Oral

11.3 Parenteral

12. Market Segmentation by Dosage Form

12.1 Solid

12.2 Liquid

13. Key Leading Countries

13.1 UK

13.2 France

13.3 Italy

13.4 Germany

13.5 Spain

14. Buying Criteria

15. Market Growth Drivers

16. Drivers and their Impact

17. Market Challenges

18. Impact of Drivers and Challenges

19. Market Trends

20. Trends and their Impact

21. Vendor Landscape

21.1 Competitive Scenario

Key News

Mergers and Acquisitions

21.2 Market Share Analysis 2014

Actavis

F. Hoffmann-La Roche

Gilead Sciences

Novartis

Vertex Pharmaceuticals

21.3 Other Prominent Vendors

22. Key Vendor Analysis

22.1 Actavis

Key Facts

Business Description

Business Segmentation

Business Segmentation by Revenue 2012 and 2013

Sales by Geography

Business Strategy

Key Information

SWOT Analysis

22.2 F. Hoffmann-La Roche

Key Facts

Business Overview

Business Segmentation

Business Segmentation by Revenue 2012 and 2013

Sales by Geography

Business Strategy

Key Information

SWOT Analysis

22.3 Gilead Sciences

Key Facts

Business Overview

Geographical Segmentation by Revenue 2013

Key Developments

SWOT Analysis

22.4 Novartis

Key Facts

Business Description

Business Segmentation

Revenue by Business Segmentation

Revenue Comparison 2012 and 2013

Sales by Geography

Business Strategy

Key Developments

SWOT Analysis

22.5 Vertex Pharmaceuticals

Key Facts

Business Overview

Business Segmentation by Revenue 2013

Business Segmentation by Revenue 2012 and 2013

Geographical Segmentation by Revenue 2013

Business Strategy

Key Developments

SWOT Analysis

23. Other Reports in this Series